INCOGNITO-SOFTWARE
14.3.2022 14:02:05 CET | Business Wire | Press release
Incognito Software Systems Inc. , a leading global provider of broadband service orchestration software solutions for digital service providers, announces that Optima Italia S.p.A. has gone live with Incognito’s Digital Experience (DX) Solution to streamline and improve the customer experience. With Incognito, Optima can centralize and streamline the management of all devices in its network to deliver an uninterrupted, high-quality customer experience using a carrier-grade solution that can scale with their network and service growth.
As a leading Italian digital company service provider, Optima offers an integrated collection of services, including electricity, gas, mobile, and Internet for business and residential markets. To support a significant and growing customer base across major centers, Optima required a solution to scale operations by replacing time- and labor-intensive manual processes with an industry awarded platform. Underpinned by Incognito’s fully featured Broadband Forum-compliant Auto Configuration Server (ACS) , the Digital Experience smart platform automates the resolution of technical issues that impact service quality.
Optima selected Incognito to support them in their automation efforts based on Incognito’s expertise enhancing subscriber experience, reducing operational costs, and supporting the delivery of innovative services into the connected home. “It was quickly apparent that Incognito could offer a great platform implementation, with system go-live in a matter of weeks,” said Paolo Primiani, Network & Voice engineer at Optima Italia.
“We are very proud to be working with Optima Italia as a technology partner for their rollout of high-speed fiber broadband services to customers across its service areas,” said Ricardo Gonzalez, VP of Sales at Incognito. “Optima is one of the leading broadband providers in Italy, respected for their dedication to customer experience. Our mission is to provide telecom operators with tools that help them increase efficiency while reducing costs, and we look forward to contributing to Optima’s success.”
The Digital Experience Solution (DX) is an industry awarded platform, used around the world by premier broadband service providers to manage and orchestrate internet of things (IoT) and customer premise equipment (CPE) with Broadband Forum’s TR-069, User Services Platform (USP / TR-369) , and other management protocols. To learn more about Digital Experience Solution and Incognito’s suite of orchestration solutions, visit www.incognito.com .
About Incognito
Incognito Software Systems Inc. provides service orchestration software and services that help digital service providers manage the next-generation broadband experience. Over 200 customers worldwide, including Claro, Cox, Digicel, Globe, and Orange, leverage Incognito solutions to fast-track the introduction of innovative broadband services over fiber, cable, and fixed wireless technologies, while delivering a great customer experience. The company is a division of the Lumine Group , a portfolio of Constellation Software Inc. , the largest independent software company in Canada. Visit www.incognito.com or follow us on LinkedIn and Twitter .
About Optima Italia
Optima Italia S.p.A., is a leading Italian digital company for the integrated provision of energy (electricity and gas) and telecommunications (internet, telephone, and mobile) services for the business and consumer markets. Optima was founded in 1999 by entrepreneurs Danilo Caruso and Alessio Matrone with the objective of creating a service company to simplify life for families and businesses. Visit www.optimaitalia.com , or follow on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005117/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom